Date: Wednesday 28 September 2022Time: 13.00-16.00 CETTitle: Psoriasis: What we have Learned and Where we are Going
Room 1
Program Chair
Lars Iversen (Denmark)
Speakers:Jonathan Barker (UK)Curdin Conrad (Switzerland)Alexander Navarini (Switzerland)Filip Rob (Czech Republic)
Lone Skov (Denmark)Chris Griffiths (UK)Peter van de Kerkhof (The Netherlands)
Part one: PROGRAM
13.00–13.05
Welcome and Introduction
13.05–13-19
Psoriasis in the Last Millennium
Peter van de Kerkhof (Netherlands)
13.19–13.33
Psoriasis and Genetics
Jonathan Barker (UK)
13.33–13.47
Psoriasis and the Immune System
Chris Griffiths (UK)
13.47–14.01
Current and Novel Treatments
Filip Rob (Czech Republic)
14.01–14.15
Biomarkers in Psoriasis Treatment – Today and in the Future
Lone Skov (Denmark)
14.15–14.29
Non-pharmacological Management Today and in the Future
Alexander Navarini (Switzerland)
14.29–14.43
Long-term Remission, Inflammatory Memory & Disease Modification
Curdin Conrad (Switzerland)
14.43–15.00
Panel Discussion
All Faculty
15.00-15.10
BREAK
Part two: POSTER PRESENTATIONS
15.10–15.11
Introduction to Poster Presentations
15.11
Blocking Interleukin-17 in Psoriasis: Real-world Experience from the PsoPlus Cohort
Lisa Schots (Belgium)
15.18
IL-17A+ mast cells in resolved psoriasis
Theresa Benezeder (Austria)
15.25
Genomic and epigenomic profiling of “invisible scar” in psoriatic resolved skin
Ameneh Ghaffarinia (Hungary)
15.32
Pathogenic relationship between Psoriasis and Obesity: An ex vivo study
Giulia Briatico (Italy)
15.39
Using single-cell transcriptomics to characterise early mechanisms of disease remission in psoriasis
Luc Francis (UK)
15.46
Cytokine imbalance during targeted therapies for psoriasis and atopic dermatitis – the yin yang of Th17 and Th2
Francesco Messina (Switzerland)
15.53
Defining Paradoxical Psoriasis and Deep Tissue Immune Cell Profiling
David Croitoru (Canada)
16.00
Closing comments and adjourn